In this study, we compared the 10-year follow-up results of patients with cT1-3N1-2 breast cancer who underwent TAS after NAC with those who underwent conventional ALND after NAC. There were no differences in the oncologic outcomes, including LRFS, DMFS, and OS, between the two groups in all of the patients. In addition, oncological outcomes showed no differences across the molecular subtypes, including HR-positive, HER2-positive, and TNBC.
Initially, the primary objective of NAC in breast cancer was to achieve resectability in inoperable locally advanced or inflammatory breast cancer23–25. Furthermore, NAC allowed the use of breast-conserving surgery rather than mastectomy and enabled monitoring of the tumor response26–28. Recently, the goal of NAC in breast cancer has changed to the achievement of pCR, which is a predictive surrogate marker of a better prognosis29,30. However, to verify the pCR of breast cancer, the exact cancer tissues should be pathologically evaluated.
Because of postoperative morbidities, such as lymphedema and nerve injury, the concept of partial ALND was introduced for patients with node-negative breast cancer by several surgeons31–33. However, rather than simply resecting part of the ALND, a targeting technique is required for node-positive breast cancer. To address this problem, it is important to mark the primary tumor and positive axillary lymph nodes for tracking during and after NAC. Several methods, including the placement of a clip or radioactive seed and charcoal tattooing, have been developed8–12. Although many novel techniques have been introduced, long-term oncologic outcomes remain underreported.
Our team reported the 5- and 10-year oncologic outcomes of patients with node-positive breast cancer who received upfront surgery with TAS compared with those that received ALND22,34. In the serial oncological outcomes, the TAS group consistently indicated non-inferiority compared with the ALND group. Additionally, a similar trend was observed in this study focusing on patients who received prior chemotherapy.
It is important to explore how TAS, a surgical technique that has not yet been standardized, can be beneficial for patients compared with the traditional ALND approach. First, by targeting the exact lesion, accurate information can be obtained to determine the tumor response after NAC in breast cancer. Although it is uncommon to miss metastasis-proven lymph nodes during conventional ALND, because the structure of lymph nodes becomes faint as they are replaced by fatty changes and fibrosis35–37, there is a possibility of this occurring. Second, the rate of lymphedema is significantly higher in patients who received ALND than in those who received TAS with axillary radiotherapy38. Because it is impossible to be completely cured and the quality of life deteriorates once lymphedema occurs, prevention is the most important consideration for lymphedema39–41. Third, the operative time can be reduced when TAS is applied, and there are fewer sequelae, including bleeding or paresthesia, because the blood vessels or nerve structures are relatively less exposed.
In this study, the authors compared the TAS group with or without axillary radiotherapy and the ALND group in patients with node-positive breast cancer who received NAC and showed consistent oncologic outcomes across the breast cancer subtypes. Although the difference between the two groups in TNBC was somewhat increased during the 10-year follow-up period, statistical significance was lacking. This indicates that the TAS procedure can be applied to patients with N1-2 breast cancer after NAC. However, if the breast cancer is higher than N3 or has a high tumor burden in the axillary lymph nodes even after NAC, it would be better to proceed with ALND.
To the best of our knowledge, this study represents a pioneering long-term oncologic report of patients with node-positive breast cancer who underwent NAC followed by TAS. Pretreatment with chemotherapy may induce lymphedema in the arms even before surgical intervention, and ALND often fails to sufficiently mitigate this condition. Consequently, TAS has emerged as a viable alternative, particularly for patients who respond positively to NAC. Despite the inherent limitations of a retrospective design and a relatively small cohort, this study underscores the potential of TAS as a standard treatment option within this patient population.